VLDL hydrolysis by LPL activates PPAR-α through generation of unbound fatty acids

Maxwell A. Ruby, Benjamin Goldenson, Gabriela Orasanu, Thomas P. Johnston, Jorge Plutzky, Ronald M. Krauss

Journal of Lipid Research · 2010 · 72 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

Recent evidence suggests that lipoproteins serve as circulating reservoirs of peroxisomal proliferator activated receptor (PPAR) ligands that are accessible through lipolysis. The present study was conducted to determine the biochemical basis of PPAR-α activation by lipolysis products and their contribution to PPAR-α function in vivo. PPAR-α activation was measured in bovine aortic endothelial cells following treatment with human plasma, VLDL lipolysis products, or oleic acid. While plasma failed to activate PPAR-α, oleic acid performed similarly to VLDL lipolysis products. Therefore, fatty acids are likely to be the PPAR-α ligands generated by VLDL lipolysis. Indeed, unbound fatty acid concentration determined PPAR-α activation regardless of fatty acid source, with PPAR-α activation occurring only at unbound fatty acid concentrations that are unachievable under physiological conditions without lipase action. In mice, a synthetic lipase inhibitor (poloxamer-407) attenuated fasting-induced changes in expression of PPAR-α target genes. Apolipoprotein CIII (apoCIII), an endogenous inhibitor of lipoprotein and hepatic lipase, regulated access to the lipoprotein pool of PPAR-α ligands, because addition of exogenous apoCIII inhibited, and removal of endogenous apoCIII potentiated, lipolytic PPAR-α activation. These data suggest that the PPAR-α response is generated by unbound fatty acids released locally by lipase activity and not by circulating plasma fatty acids. Recent evidence suggests that lipoproteins serve as circulating reservoirs of peroxisomal proliferator activated receptor (PPAR) ligands that are accessible through lipolysis. The present study was conducted to determine the biochemical basis of PPAR-α activation by lipolysis products and their contribution to PPAR-α function in vivo. PPAR-α activation was measured in bovine aortic endothelial cells following treatment with human plasma, VLDL lipolysis products, or oleic acid. While plasma failed to activate PPAR-α, oleic acid performed similarly to VLDL lipolysis products. Therefore, fatty acids are likely to be the PPAR-α ligands generated by VLDL lipolysis. Indeed, unbound fatty acid concentration determined PPAR-α activation regardless of fatty acid source, with PPAR-α activation occurring only at unbound fatty acid concentrations that are unachievable under physiological conditions without lipase action. In mice, a synthetic lipase inhibitor (poloxamer-407) attenuated fasting-induced changes in expression of PPAR-α target genes. Apolipoprotein CIII (apoCIII), an endogenous inhibitor of lipoprotein and hepatic lipase, regulated access to the lipoprotein pool of PPAR-α ligands, because addition of exogenous apoCIII inhibited, and removal of endogenous apoCIII potentiated, lipolytic PPAR-α activation. These data suggest that the PPAR-α response is generated by unbound fatty acids released locally by lipase activity and not by circulating plasma fatty acids. The peroxisomal proliferator activated receptor (PPAR) family of nuclear hormone receptors functions as transcriptional nodal points in the regulation of energy metabolism and inflammation (1.Brown J.D. Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.Circulation. 2007; 115: 518-533Crossref PubMed Scopus (275) Google Scholar). Three PPAR isotypes have been identified: PPAR-α and PPAR-δ, which stimulate fatty acid oxidation and share many target genes, but still differ in tissue distribution and functional effects, and PPAR-γ, which activates lipid storage and adipogenesis. In vitro analyses demonstrate that PPARs are activated by high concentrations of fatty acids and their derivatives, although the physiological context and relevance of these effects have remained unclear (2.Kliewer S.A. Sundseth S.S. Jones S.A. Brown P.J. Wisely G.B. Koble C.S. Devchand P. Wahli W. Willson T.M. Lenhard J.M. et al.Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.Proc. Natl. Acad. Sci. USA. 1997; 94: 4318-4323Crossref PubMed Scopus (1859) Google Scholar, 3.Forman B.M. Chen J. Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.Proc. Natl. Acad. Sci. USA. 1997; 94: 4312-4317Crossref PubMed Scopus (1844) Google Scholar). Together, these data have led to the view of PPARs as lipid sensors; despite this, the upstream factors determining generation and delivery of the lipid ligands are poorly understood. Intracellular fatty acids can be generated by three main sources: de novo lipogenesis, enzymatic hydrolysis, or uptake from extracellular sources. Plasma NEFA circulate bound to albumin or can be generated locally by vascular lipases acting on lipoproteins. Lipolytic processing of lipoproteins appears to be an important source of PPAR-α and -δ ligands as reported by us and others (4.Chawla A. Lee C.H. Barak Y. He W. Rosenfeld J. Liao D. Han J. Kang H. Evans R.M. PPARdelta is a very low-density lipoprotein sensor in macrophages.Proc. Natl. Acad. Sci. USA. 2003; 100: 1268-1273Crossref PubMed Scopus (266) Google Scholar, 5.Lee C.H. Kang K. Mehl I.R. Nofsinger R. Alaynick W.A. Chong L.W. Rosenfeld J.M. Evans R.M. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage.Proc. Natl. Acad. Sci. USA. 2006; 103: 2434-2439Crossref PubMed Scopus (79) Google Scholar, 6.Ziouzenkova O. Perrey S. Asatryan L. Hwang J. MacNaul K.L. Moller D.E. Rader D.J. Sevanian A. Zechner R. Hoefler G. et al.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735Crossref PubMed Scopus (194) Google Scholar). In vitro, LPL-mediated lipolysis of VLDL stimulates PPAR-α and PPAR-δ activity and downstream responses, whereas similar quantities of NEFA from plasma fail to recapitulate these effects (4.Chawla A. Lee C.H. Barak Y. He W. Rosenfeld J. Liao D. Han J. Kang H. Evans R.M. PPARdelta is a very low-density lipoprotein sensor in macrophages.Proc. Natl. Acad. Sci. USA. 2003; 100: 1268-1273Crossref PubMed Scopus (266) Google Scholar, 5.Lee C.H. Kang K. Mehl I.R. Nofsinger R. Alaynick W.A. Chong L.W. Rosenfeld J.M. Evans R.M. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage.Proc. Natl. Acad. Sci. USA. 2006; 103: 2434-2439Crossref PubMed Scopus (79) Google Scholar, 6.Ziouzenkova O. Perrey S. Asatryan L. Hwang J. MacNaul K.L. Moller D.E. Rader D.J. Sevanian A. Zechner R. Hoefler G. et al.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735Crossref PubMed Scopus (194) Google Scholar). Lipolysis of HDL by endothelial lipase also generates PPAR-α ligands (7.Ahmed W. Orasanu G. Nehra V. Asatryan L. Rader D.J. Ziouzenkova O. Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.Circ. Res. 2006; 98: 490-498Crossref PubMed Scopus (75) Google Scholar). In mouse models, transgenic LPL overexpression and treatment with a pharmacological LPL activator, NO-1886, indicate that LPL lipolytic products are sufficient to promote PPAR-α-dependent peroxisomal proliferation and induction of PPAR-α target genes; likewise, cardiac-specific LPL-deficient animals have reduced expression of PPAR-α target genes (6.Ziouzenkova O. Perrey S. Asatryan L. Hwang J. MacNaul K.L. Moller D.E. Rader D.J. Sevanian A. Zechner R. Hoefler G. et al.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735Crossref PubMed Scopus (194) Google Scholar, 8.Augustus A.S. Buchanan J. Park T.S. Hirata K. Noh H.L. Sun J. Homma S. D'Armiento J. Abel E.D. Goldberg I.J. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction.J. Biol. Chem. 2006; 281: 8716-8723Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar, 9.Doi M. Kondo Y. Tsutsumi K. Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver.Metabolism. 2003; 52: 1547-1550Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar). Together these data reveal that specific lipoproteins serve as circulating pools of PPAR-α and δ ligands. The unexplained observation that VLDL lipolysis products activate PPAR-α whereas NEFA from plasma do not remains a key unresolved issue in understanding how fatty acids and their handling influence cellular responses. Differences in chemical composition could potentially account for the effective activation of PPAR-α by triglyceride-rich lipoprotein lipolysis metabolites as opposed to plasma NEFA. For example, VLDL contains retinoids, phospholipids, and other nonfatty acid compounds that may play a role in activating PPAR-α. Alternatively, the source and delivery of the fatty acid may alter its cellular metabolism and signaling properties. For example, arachidonic acid released by phospholipase A2-mediated cleavage of phospholipids is preferentially channeled to eicosanoid biosynthesis. Therefore, it is possible that differences in chemistry or delivery of lipolysis products underlie their preferential activation of PPAR-α. Moreover, the activity of LPL is under the control of multiple additional inputs, including the action of apolipoprotein CIII (apoCIII), an endogenous LPL inhibitor. Whether regulators of LPL activity such as apoCIII modulate PPAR activity remains unknown. In the current study, we assessed the biochemical basis of lipolytic PPAR-α activation, the role of apoCIII in determining PPAR-α activity, and the evidence for their contribution to PPAR-α function in vivo. Bovine aortic endothelial cells (BAEC) were transfected with a PPAR-α transactivation assay as previously described (6.Ziouzenkova O. Perrey S. Asatryan L. Hwang J. MacNaul K.L. Moller D.E. Rader D.J. Sevanian A. Zechner R. Hoefler G. et al.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735Crossref PubMed Scopus (194) Google Scholar). Briefly, BAEC were grown in Dulbecco's Modified Eagle's Medium (Invitrogen) supplemented with 10% fetal bovine serum (Omega Scientific), penicillin/streptomycin (Invitrogen), and l-glutamine (Invitrogen). Cells were seeded in 24-well plates and transfected as previously described using Fugene HD transfection reagent (Roche Diagnostics) (6.Ziouzenkova O. Perrey S. Asatryan L. Hwang J. MacNaul K.L. Moller D.E. Rader D.J. Sevanian A. Zechner R. Hoefler G. et al.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735Crossref PubMed Scopus (194) Google Scholar). Twenty-four hours after transfection, cells were treated as indicated for 18 h. Cells were harvested and luciferase and β-galactosidase activity were measured by addition of substrate, luciferin (BD Biosciences) and chlorophenol red β-galactoside (Sigma), respectively, with quantification of resulting photoemission or absorbance. PPAR-α activation was calculated as the ratio of luciferase activity to β-galactosidase activity. Cell culture medium was analyzed for NEFA content using an enzymatic colorimetric kit (Wako). The equilibrium concentration of unbound oleate was calculated as described by Spector et al. (10.Spector A.A. Fletcher J.E. Ashbrook J.D. Analysis of long-chain free fatty acid binding to bovine serum albumin by determination of stepwise equilibrium constants.Biochemistry. 1971; 10: 3229-3232Crossref PubMed Scopus (207) Google Scholar). To assess fatty acid uptake, BAEC were incubated with 90 μM unlabeled oleic acid spiked with 9,10-3H oleic acid (1 µCi/well; 33.4 Ci/mmol; Perkin Elmer) or 10 μg/ml VLDL labeled, as previously described, with 3H trioleate (Perkin Elmer) as indicated for 20 min (11.Seo T. Al-Haideri M. Treskova E. Worgall T.S. Kako Y. Goldberg I.J. Deckelbaum R.J. Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface proteoglycans and is independent of scavenger receptor class B type 1.J. Biol. Chem. 2000; 275: 30355-30362Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar). Cells were washed with ice-cold PBS and lysed with 0.1 M NaOH. Cell lysate was analyzed for protein concentration and cell-associated CPM. All experiments were performed in triplicate. All plasma samples were obtained by the Cholesterol Research Center at Children's Hospital Oakland Research Institute. Blood was collected from healthy subjects after an overnight fast. The protocol was approved by the Institutional Review Board of Children's Hospital and Research Center Oakland, and informed consent was obtained from all volunteers. An aliquot of plasma was added to an immunoaffinity column prepared from purified goat anti-human apoCIII sera (International Immunology Corp.) covalently linked to Affigel-10 (BioRad Laboratories) following the manufacturer's instructions. Following overnight at the unbound of was collected and were from plasma or the unbound immunoaffinity column by was measured by assay and was measured in by assay with goat anti-human apoCIII (International Immunology content was by enzymatic assay were for to treatment and three were with and to were with and for h. were with and for h. were and all harvested and plasma samples were at The treatment protocol was approved by the Institutional and at the of was from tissue using the kit was performed on the using in All genes were to an endogenous control gene The peroxisomal protein medium lipoprotein lipase and with was to for differences in treatment were to differences in PPAR-α activation lipoprotein from the All analyses were performed using are as To differences in chemistry the in PPAR-α activation with plasma and lipolysis products, the of oleic and plasma to stimulate PPAR-α was on a basis in acid activated PPAR-α similarly to VLDL lipolytic products, plasma failed to activate PPAR-α despite the of fatty acids that oleic acid is the fatty acid in plasma, the of VLDL to activate PPAR-α in to plasma likely from delivery To PPAR-α activation on the generation of unbound fatty acids, BAEC were incubated with and concentrations of in with PPAR-α activation in a with at albumin PPAR-α activation by a synthetic was not by addition of albumin at low oleic acid in fatty acid uptake is to at physiological NEFA the unbound fatty acid concentration the of uptake D. concentrations oleate uptake by cardiac and is a function of the unbound oleate are with the PubMed Scopus Google Scholar). To determine the fatty acid uptake and PPAR-α activation, fatty acid uptake and PPAR-α activity were measured in in BAEC treated with concentrations of unbound oleic acid generated by the albumin content added to 90 μM oleic acid. fatty acid uptake and PPAR-α activation increased with unbound oleic acid concentration the with at for fatty acid uptake and for PPAR-α activation. experiments with unbound oleic acid concentrations that fatty acid uptake a with PPAR-α activation fatty acid uptake was unachievable at physiological unbound fatty acid concentrations the of plasma NEFA to activate PPAR-α D. concentrations oleate uptake by cardiac and is a function of the unbound oleate are with the PubMed Scopus Google Scholar, free fatty acid in human Res. Full Text PDF PubMed Google Scholar). VLDL treated with LPL generated fatty acid uptake sufficient to activate PPAR-α. To the contribution of lipase action to the in generation of PPAR-α ligands, the transcriptional response of PPAR-α target genes to was in treated with a lipase the or control at the of a fast. concentrations whereas In increased hepatic and cardiac expression of a PPAR-α target gene including and In treated with hepatic transcriptional changes in response to were for and for and for and treatment the response for all PPAR-α target genes in the heart of lipolytic activity may also alter downstream PPAR-α activation, the role of a inhibitor of in lipolytic of PPAR-α ligands was of apoCIII or a synthetic lipase to VLDL the resulting PPAR-α activation, with of NEFA the cell culture To determine changes in endogenous apoCIII content alter lipolytic to PPAR-α ligands, PPAR-α activation in response to VLDL of apoCIII by immunoaffinity was with activation in response to VLDL from the VLDL of the of BAEC were incubated with VLDL or VLDL from the VLDL activated PPAR-α to a the VLDL from the The data demonstrate the biochemical basis for the activation of PPAR-α by lipolysis of triglyceride-rich lipoproteins. a LPL lipolysis products activate PPAR-α similarly to oleic the plasma fatty acid. likely for preferential PPAR-α activation by VLDL lipolysis products. of albumin to the treatment PPAR-α activation, that lipolysis products activate PPAR-α by unbound fatty acids. fatty acids be from albumin to for tissue uptake, the unbound fatty acid concentration is a of uptake D. concentrations oleate uptake by cardiac and is a function of the unbound oleate are with the PubMed Scopus Google Scholar). that fatty acid uptake to activation of PPAR-α. In PPAR-α activation requires a of fatty acid uptake that is unachievable at physiological plasma unbound fatty acid a for the of plasma to activate PPAR-α despite the of fatty acids. at physiological of to lipase action generates an unbound fatty acid concentration sufficient to fatty acid uptake the PPAR-α activation is by the of plasma to lipase in or in vitro to activate PPAR-α (6.Ziouzenkova O. Perrey S. Asatryan L. Hwang J. MacNaul K.L. Moller D.E. Rader D.J. Sevanian A. Zechner R. Hoefler G. et al.Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735Crossref PubMed Scopus (194) Google Scholar). was in an gene and not demonstrate PPAR-α The fatty acid uptake and PPAR-α activation may of fatty acid acid uptake is the of and R.M. D. of oleate binding to plasma and its uptake by Full Text PDF PubMed Scopus Google Scholar). acid uptake in the physiological of unbound fatty acids is by the in the current study, failed to activate PPAR-α. The likely the action of fatty acid such as of in or in vitro lipid uptake without PPAR-α activation R. Goldberg I.J. of in peroxisome proliferator-activated transgenic by of lipoprotein lipase of cardiac and peroxisome proliferator-activated PubMed Scopus Google Scholar, J. Han M. A. M. Res. 2007; 100: PubMed Scopus Google Scholar). plasma NEFA may fail to activate PPAR-α because are by at the unbound fatty acid concentrations in the lipolytic a of fatty acid uptake may and to PPAR-α activation. The of the of fatty acid uptake and how it may target fatty acids to the for signaling requires These data suggest that VLDL can serve as a source of PPAR-α ligands by high concentrations of unbound fatty acids. have that fatty acids from lipolysis of triglyceride-rich lipoproteins with plasma fatty acid uptake is regulated by the activity of likely as a of the high concentration of unbound fatty acids generated in the LPL P.J. H. of fatty acids released from lipolysis of plasma to plasma fatty acid and fatty acid 2003; 52: PubMed Scopus Google Scholar). In LPL activity been to a of the fatty acids by the heart and other A. H. G. A. Park Zechner R. Goldberg I.J. of lipoprotein lipase plasma lipoprotein metabolism and cardiac gene Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, P.J. of plasma metabolism on lipid storage in using mouse PubMed Scopus (79) Google Scholar). increased lipase activity, and not the increased of NEFA from is likely to be for increased PPAR-α function in the is by that of the fasting-induced in PPAR-α gene lipoprotein and endothelial and hepatic lipase, the resulting in PPAR-α signaling be to the action of a specific many signaling are the to the fasting-induced in genes and are to be on PPAR-α role for the peroxisome proliferator-activated receptor alpha in the cellular the mouse as a of fatty acid oxidation Natl. Acad. Sci. USA. PubMed Scopus Google Scholar). hepatic expression of and in response to was by The of an on is with data from in role for the peroxisome proliferator-activated receptor alpha in the cellular the mouse as a of fatty acid oxidation Natl. Acad. Sci. USA. PubMed Scopus Google Scholar, S. J. J.M. Wahli W. Peroxisome proliferator-activated receptor alpha the response to 103: PubMed Scopus Google Scholar). In the we that attenuated fasting-induced in expression of the PPAR-α target genes that were Together with the in vitro these suggest that lipase activity is to activate PPAR-α. these data are with is not a specific inhibitor of lipase activity, and other effects may have not fatty acid uptake or lipase activity and direct effects on PPAR-α function D.J. The induction of in is not through PubMed Scopus (13) Google Scholar, of in the PubMed Scopus Google Scholar, P. Hwang A. M. H. M. R. Goldberg I.J. of with triglyceride-rich the in J. PubMed Scopus Google Scholar). LPL expression of PPAR-α target genes and cardiac by PPAR-α overexpression R. Goldberg I.J. of in peroxisome proliferator-activated transgenic by of lipoprotein lipase of cardiac and peroxisome proliferator-activated PubMed Scopus Google Scholar). The current study the of LPL in PPAR-α activation in and the to demonstrate that pharmacological of LPL PPAR-α activation by endogenous of other a key role of lipase in the generation of PPAR ligands. Lipolysis of HDL by endothelial lipase expression and leukocyte in a PPAR-α-dependent (7.Ahmed W. Orasanu G. Nehra V. Asatryan L. Rader D.J. Ziouzenkova O. Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.Circ. Res. 2006; 98: 490-498Crossref PubMed Scopus (75) Google Scholar). LPL animals reduced cardiac expression of PPAR-α target genes despite increased uptake of plasma NEFA A. H. G. A. Park Zechner R. Goldberg I.J. of lipoprotein lipase plasma lipoprotein metabolism and cardiac gene Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, A.S. Kako Y. H. Goldberg I.J. of delivery to cardiac of lipoprotein lipolysis uptake of J. 2003; PubMed Scopus Google Scholar). LPL in but not peroxisomal and increased and of PPAR-α and -δ activation A. A. T. K. R. overexpression of fatty acid oxidation by plasma and fatty acids, and plasma glucose and Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, S. H. A. R. G. Hoefler G. W. Zechner R. overexpression of lipoprotein lipase a by proliferation of and in transgenic PubMed Scopus (194) Google Scholar). to lipase activity also proliferation and binding of PPAR-δ to the PPAR response in the in P. J.M. Han E. Chen M. plasma fatty acid concentration increased of in Natl. Acad. Sci. USA. 2007; PubMed Scopus Google Scholar). NO-1886, a pharmacological LPL activates fatty acid oxidation genes and and hepatic effects with PPAR-α activation M. Kondo Y. Tsutsumi K. Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver.Metabolism. 2003; 52: 1547-1550Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar). the activity of LPL in been to regulate protein a PPAR-α and -δ of NEFA D. Zechner R. activity of lipoprotein lipase in the expression of protein in transgenic mouse J. PubMed Scopus Google Scholar). these in the role of lipolysis products as of PPAR-α and -δ function of plasma NEFA on the delivery of PPAR-α ligands from extracellular fatty acids generated by de novo or enzymatic hydrolysis may also activate PPAR-α. PPAR-α-dependent gene expression in fatty acid suggests a specific role for de novo products as PPAR-α ligands Y. K. T. J. hepatic activates to and Full Text Full Text PDF PubMed Scopus Google Scholar). The bound to PPAR-α was as I.J. L. J. of a endogenous for in Full Text Full Text PDF PubMed Scopus Google Scholar). of on PPAR-α-dependent gene that of PPAR-α ligands J. H. L. P. S.S. of hepatic without glucose Natl. Acad. Sci. USA. 2006; 103: PubMed Scopus Google Scholar). in vitro that of access to hepatic lipid PPAR-α activity J.M. A.S. hydrolysis peroxisome proliferator-activated receptor alpha Res. Full Text Full Text PDF PubMed Scopus Google Scholar). the for generation of PPAR-α ligands, may be to cells with low of and The evidence for LPL-mediated PPAR-α activation suggests that other that determine LPL activity also influence PPAR-α activation. The biochemical function of apoCIII it a likely candidate for of lipolytic PPAR-α and -δ activation. an is linked to and by and but the these remains P. E. and and of in the Cholesterol and 2000; PubMed Scopus Google Scholar). In vitro, apoCIII hepatic lipase, and hepatic of in lipoprotein functional differences and Biol. PubMed Scopus Google Scholar). apoCIII been to have a of including activation of receptor A. M. M. S. S. P. K. M. receptor apolipoprotein Res. 103: PubMed Scopus Google Scholar). The present demonstrate that apoCIII can play an additional role in and functions by lipolytic generation of PPAR-α ligands. apoCIII expression is and LPL activity is by PPAR-α, a may O. Plutzky J. Lipolytic PPAR the of and PubMed Scopus Google Scholar). with high apoCIII may have generation of endogenous PPAR-α ligands and be likely to from synthetic PPAR-α ligands. In demonstrate that lipolysis of VLDL the unbound fatty acid concentration for activation of PPAR-α by an extracellular source and that apoCIII is of in The for apolipoprotein CIII bovine aortic endothelial cell medium peroxisomal protein peroxisomal proliferator activated receptor

References

33